Home    Back

 130. Congenital insensitivity to pain with anhydrosis
 [ 1 clinical trial,    9 drugs（DrugBank: 7 drugs),    4 target genes / 34 target pathways ] 

Searched query = "Congenital insensitivity to pain with anhydrosis", "CIPA", "Hereditary sensory and autonomic neuropathy type IV", "HSAN4", "Hereditary sensory and autonomic neuropathy type V", "HSAN5"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03070470March 14, 201716 December 2017CiPA Phase 1 ECG Biomarker Validation StudyComprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)Drug-induced QT Prolongation;Pharmacokinetics;PharmacodynamicsDrug: Ranolazine;Drug: Verapamil;Drug: Lopinavir / Ritonavir;Drug: Chloroquine;Drug: Placebo;Drug: Dofetilide and DiltiazemFood and Drug Administration (FDA)Spaulding Clinical Research LLCNot recruiting18 Years50 YearsAll57Phase 1United States